Conference Coverage
Conference Coverage
Steroid complications in GVHD common, boost costs of care
Conference Coverage
CAR T-cell products shine in real-world setting, reveal new insights
Real-world CAR-T experience provides new insights for predicting outcomes in patients with DLBCL.
Conference Coverage
Chronic GVHD therapies offer hope for treating refractory disease
Conference Coverage
Four-item prognostic index predicts survival in adult Burkitt lymphoma
Conference Coverage
Synthetic lethality: Triple combination is a viable strategy for B-cell malignancies
Conference Coverage
ZUMA-12 study shows frontline axi-cel has substantial activity in high-risk large B-cell lymphoma
Conference Coverage
Pediatric regimens better for adolescents/young adults with aggressive B-cell NHL
Conference Coverage
Bispecific antibody odronextamab demonstrates durable complete responses in refractory NHL
Conference Coverage
Fixed duration ibrutinib/venetoclax appears feasible for some CLL/SLL patients
Conference Coverage
ZUMA-5: Axi-cel yields high response rate in indolent NHL
The CAR T-cell therapy had a favorable safety profile and a median duration of response that had not been reached at a median of 17.5 months...